These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 28191373)

  • 1. Capecitabine-Associated Loss of Fingerprints: Report of Capecitabine-Induced Adermatoglyphia in Two Women with Breast Cancer and Review of Acquired Dermatoglyphic Absence in Oncology Patients Treated with Capecitabine.
    Cohen PR
    Cureus; 2017 Jan; 9(1):e969. PubMed ID: 28191373
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Capecitabine-Associated Loss of Fingerprints: A Case Report of a 62-Year-Old Man With Colorectal Cancer Suffering From Capecitabine-Induced Adermatoglyphia.
    Dawood T; Zahir MN; Afzal M; Rashid YA
    Cureus; 2021 Jun; 13(6):e15519. PubMed ID: 34268045
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Capecitabine induced fingerprint loss: Case report and review of the literature.
    Deneken-Hernandez Z; Cherem-Kibrit M; Gutiérrez-Andrade L; Rodríguez-Gutiérrez G; Colmenero-Mercado JO
    J Oncol Pharm Pract; 2022 Mar; 28(2):495-499. PubMed ID: 34609922
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Capecitabine: a review.
    Walko CM; Lindley C
    Clin Ther; 2005 Jan; 27(1):23-44. PubMed ID: 15763604
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemotherapy and fingerprint loss: beyond cosmetic.
    Al-Ahwal MS
    Oncologist; 2012; 17(2):291-3. PubMed ID: 22298801
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Capecitabine induced fingerprint changes.
    Yaghobi Joybari A; Azadeh P; Ghiasi HA; Amouzegar A; Yaseri M; Amini A; Farasatinasab M; Mokhtari M
    J Clin Pharm Ther; 2019 Oct; 44(5):780-787. PubMed ID: 31254478
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Loss of Fingerprints as a Side Effect of Capecitabine Therapy: Case Report and Literature Review.
    Zhao J; Zhang X; Cui X; Wang D; Zhang B; Ban L
    Oncol Res; 2020 Feb; 28(1):103-106. PubMed ID: 31558182
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of hand-foot syndrome induced by capecitabine.
    Gressett SM; Stanford BL; Hardwicke F
    J Oncol Pharm Pract; 2006 Sep; 12(3):131-41. PubMed ID: 17022868
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adermatoglyphia: Barriers to Biometric Identification and the Need for a Standardized Alternative.
    Sarfraz N
    Cureus; 2019 Feb; 11(2):e4040. PubMed ID: 31011502
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fingerprint Change: Not Visible, But Tangible.
    Negri FV; De Giorgi A; Bozzetti C; Squadrilli A; Petronini PG; Leonardi F; Bisogno L; Garofano L
    J Forensic Sci; 2017 Sep; 62(5):1372-1373. PubMed ID: 28605025
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fingerprint changes among cancer patients treated with paclitaxel.
    Azadeh P; Dashti-Khavidaki S; Joybari AY; Sarbaz S; Jafari A; Yaseri M; Amini A; Farasatinasab M
    J Cancer Res Clin Oncol; 2017 Apr; 143(4):693-701. PubMed ID: 27988843
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Capecitabine: a review of its pharmacology and therapeutic efficacy in the management of advanced breast cancer.
    Wagstaff AJ; Ibbotson T; Goa KL
    Drugs; 2003; 63(2):217-36. PubMed ID: 12515569
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Fingerprints: origin, uses and challenges in the face of its verification failure].
    Guízar-Sahagún G; Grijalva-Otero I; Madrazo-Navarro I
    Rev Med Inst Mex Seguro Soc; 2021 Nov; 59(6):568-573. PubMed ID: 34913636
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incidence and severity of hand-foot syndrome in cancer patients receiving infusional 5-fluorouracil or oral capecitabine-containing chemotherapy regimens.
    Abdul Kareem S; Joseph SG; Wilson A; Kareem SA; Kunjumon Vilapurathu J
    J Oncol Pharm Pract; 2024 Jan; ():10781552241228175. PubMed ID: 38263642
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The immigration delay disease: adermatoglyphia-inherited absence of epidermal ridges.
    Burger B; Fuchs D; Sprecher E; Itin P
    J Am Acad Dermatol; 2011 May; 64(5):974-80. PubMed ID: 20619487
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Capecitabine and the Risk of Fingerprint Loss.
    van Doorn L; Veelenturf S; Binkhorst L; Bins S; Mathijssen R
    JAMA Oncol; 2017 Jan; 3(1):122-123. PubMed ID: 27560202
    [No Abstract]   [Full Text] [Related]  

  • 17. Capecitabine (Xeloda) improves medical resource use compared with 5-fluorouracil plus leucovorin in a phase III trial conducted in patients with advanced colorectal carcinoma.
    Twelves C; Boyer M; Findlay M; Cassidy J; Weitzel C; Barker C; Osterwalder B; Jamieson C; Hieke K;
    Eur J Cancer; 2001 Mar; 37(5):597-604. PubMed ID: 11290435
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase I study of capecitabine in combination with vinorelbine in advanced breast cancer.
    Lorusso V; Crucitta E; Silvestris N; Guida M; Misino A; Latorre A; De Lena M
    Clin Breast Cancer; 2003 Jun; 4(2):138-41. PubMed ID: 12864942
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systematic review of the clinical effectiveness and cost-effectiveness of capecitabine (Xeloda) for locally advanced and/or metastatic breast cancer.
    Jones L; Hawkins N; Westwood M; Wright K; Richardson G; Riemsma R
    Health Technol Assess; 2004 Feb; 8(5):iii, xiii-xvi, 1-143. PubMed ID: 14960257
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Coming to grips with hand-foot syndrome. Insights from clinical trials evaluating capecitabine.
    Scheithauer W; Blum J
    Oncology (Williston Park); 2004 Aug; 18(9):1161-8, 1173; discussion 1173-6, 1181-4. PubMed ID: 15471200
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.